-
公开(公告)号:US20210347756A1
公开(公告)日:2021-11-11
申请号:US17102628
申请日:2020-11-24
IPC分类号: C07D401/04 , C07D401/12 , C07D235/30 , C07D403/14 , C07D409/12 , C07D239/84 , C07D403/12 , C07D405/12 , C07D471/04 , C07D475/00
摘要: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
-
公开(公告)号:US20200317635A1
公开(公告)日:2020-10-08
申请号:US16838656
申请日:2020-04-02
发明人: James Bradner , Dennis Buckley , Georg Winter
IPC分类号: C07D401/04 , C07D471/04 , C07D471/14 , C07D401/14 , C07D475/00 , C07D487/04 , C07D495/14 , C07J43/00
摘要: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
-
公开(公告)号:US10450297B2
公开(公告)日:2019-10-22
申请号:US15946117
申请日:2018-04-05
申请人: Pfizer, Inc.
发明人: Michael J. Luzzio , Kevin D. Freeman-Cook , Samit K. Bhattacharya , Matthew M. Hayward , Catherine A. Hulford , Christopher L. Autry , Xumiao Zhao , Jun Xiao , Kendra L. Nelson
IPC分类号: C07D401/12 , C07D239/48 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D241/20 , C07D475/00
摘要: The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
-
公开(公告)号:US20190290654A1
公开(公告)日:2019-09-26
申请号:US16372080
申请日:2019-04-01
发明人: John Patrick Maxwell , Paul S. Charifson , Qing Tang , Steven M. Ronkin , Katrina Lee Jackson , Albert Charles Pierce , David J. Lauffer , Pan Li , Simon Giroux , Jinwang Xu , Kevin Michael Cottrell , Mark A. Morris , Nathan D. Waal , John J. Court , Wenxin Gu , Hongbo Deng
IPC分类号: A61K31/5377 , C07D403/12 , C07D241/42 , A61K31/506 , C07D513/04 , C07D498/08 , C07D491/048 , C07D487/04 , C07D475/00 , C07D473/40 , C07D471/04 , C07D417/12 , C07D413/12 , C07D405/14 , C07D405/12 , C07D403/14 , C07D401/14 , C07D241/40 , C07D491/08 , C07D271/12 , C07D401/12 , C07D413/14 , C07D491/056 , C07D491/052 , C07D241/44 , C07D413/04 , A61K31/5386
摘要: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号:US10125114B2
公开(公告)日:2018-11-13
申请号:US15632023
申请日:2017-06-23
发明人: James Bradner , Dennis Buckley , Georg Winter
IPC分类号: A61K31/519 , C07D401/04 , C07D471/04 , C07D471/14 , C07D401/14 , C07D475/00 , C07D487/04 , C07D495/14 , C07J43/00
摘要: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.
-
公开(公告)号:US20180311254A1
公开(公告)日:2018-11-01
申请号:US15965489
申请日:2018-04-27
发明人: John Patrick Maxwell , Paul S. Charifson , Qing Tang , Steven M. Ronkin , Katrina Lee Jackson , Albert Charles Pierce , David J. Lauffer , Pan Li , Simon Giroux , Jinwang Xu , Kevin Michael Cottrell , Mark A. Morris , Nathan D. Waal , John J. Court , Wenxin Gu , Hongbo Deng
IPC分类号: A61K31/5377 , C07D403/12 , C07D241/42 , A61K31/506 , C07D513/04 , C07D498/08 , C07D491/048 , C07D487/04 , C07D475/00 , C07D473/40 , C07D471/04 , C07D417/12 , C07D413/12 , C07D405/14 , C07D405/12 , C07D403/14 , C07D401/14 , C07D241/40 , C07D491/08 , C07D271/12 , C07D401/12 , C07D413/14 , C07D491/056 , C07D491/052 , C07D241/44 , C07D413/04 , A61K31/5386
CPC分类号: A61K31/5377 , A61K31/506 , A61K31/5386 , C07D241/40 , C07D241/42 , C07D241/44 , C07D271/12 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D473/40 , C07D475/00 , C07D487/04 , C07D491/048 , C07D491/052 , C07D491/056 , C07D491/08 , C07D498/08 , C07D513/04
摘要: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号:US20180298005A1
公开(公告)日:2018-10-18
申请号:US15763690
申请日:2016-09-28
申请人: Steven Richard BRUNETTE , Johanna CSENGERY , Robert Owen HUGHES , Xiang LI , Robert SIBLEY , Michael Robert TURNER , Zhaoming XIONG , Boehringer Ingelheim International GmbH
发明人: Steven Richard BRUNETTE , Johanna CSENGERY , Robert Owen HUGHES , Xiang LI , Robert SIBLEY , Michael Robert TURNER , Zhaoming XIONG
IPC分类号: C07D475/00
CPC分类号: C07D475/00 , A61K31/519 , C07D475/10
摘要: The present invention encompasses compounds of formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.
-
公开(公告)号:US09771351B2
公开(公告)日:2017-09-26
申请号:US14908945
申请日:2014-07-29
发明人: Hiroshi Ishida , Keiichi Motosawa , Yusuke Miura , Ryuichiro Nakai , Ryoko Okada , Yuichi Takahashi
IPC分类号: C07D401/14 , C07D475/00 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04 , C07D491/052 , C07D491/056 , C07D498/04 , C07D519/00
CPC分类号: C07D401/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D475/00 , C07D487/04 , C07D491/052 , C07D491/056 , C07D498/04 , C07D519/00
摘要: A Wnt signaling inhibitor which comprises, as an active ingredient, a fused-ring heterocyclic compound represented by the following formula (IA) or a pharmaceutically acceptable salt thereof, and the like are provided: (wherein, n1A represents 0 or 1; n2A and n3A may be the same or different, and each represents 1 or 2; ROA represents optionally substituted aryl or the like; R2A represents a hydrogen atom or the like; R3A represents an optionally substituted aromatic heterocyclic group or the like; X1A, X2A, X3A and X4A each represent CH or the like; Y1A represents CH2 or the like; Y2A represents N or the like; and LA represents CH2 or the like).
-
公开(公告)号:US09708328B2
公开(公告)日:2017-07-18
申请号:US15047038
申请日:2016-02-18
发明人: Pierre Jean-Marie Bernard Raboisson , Dominique Louis Nestor Ghislain Surleraux , Tse-I Lin , Oliver Lenz , Kenneth Alan Simmen
IPC分类号: C07D475/00 , A61K31/495 , C07D475/10 , A61K31/519 , C07D487/04 , A61K31/5377 , A61K45/06
CPC分类号: C07D475/10 , A61K31/519 , A61K31/5377 , A61K45/06 , C07D487/04 , Y02A50/385 , Y02A50/387 , A61K2300/00
摘要: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.
-
公开(公告)号:US09637489B2
公开(公告)日:2017-05-02
申请号:US14845603
申请日:2015-09-04
IPC分类号: A01N43/58 , A01N43/60 , A61K31/50 , A61K31/495 , C07D475/00 , C07D487/04 , C07D475/10 , C07D475/02 , C07D475/06 , C07D475/08 , A61K31/519 , A61K31/53 , A61K31/5377
CPC分类号: C07D475/00 , A61K31/519 , A61K31/53 , A61K31/5377 , C07D475/02 , C07D475/06 , C07D475/08 , C07D475/10 , C07D487/04 , Y02A50/411
摘要: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.
-
-
-
-
-
-
-
-
-